Singapore Clinical Trial: A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)

Posted On: 2026-03-28

Singapore, March 28 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)'. The following are the other relevant details related to the trial:

Therapeutic Area: Cardiology

Trial Centre(s): National University Hospital Singapore General Hospital

Trial Status: NA

Principal Investigator(s): Dr Lin Weiqin Dr Kaavya Narasimhalu

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Singapore Clinical Trial: A Phase 3, Open-Label, Multicenter, Extension Study of Acoramidis in Patients with Newly Diagnosed Variant Transthyretin Amyloid Cardiomyopathy (ACT-EARLY OLE)